These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 16262557)

  • 21. Cardiovascular risks of cyclooxygenase inhibition.
    Stacy ZA; Dobesh PP; Trujillo TC
    Pharmacotherapy; 2006 Jul; 26(7):919-38. PubMed ID: 16803424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
    Wong M; Chowienczyk P; Kirkham B
    Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
    Bijlsma JW; Lems WF; van de Laar MA
    Ned Tijdschr Geneeskd; 2007 Apr; 151(14):795-8. PubMed ID: 17469317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
    Rostom A; Moayyedi P; Hunt R;
    Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COXIBs and non-selective NSAIDs in the gastroenterological setting: what should patients and physicians do?
    Lazzaroni M; Battocchia A; Bianchi Porro G
    Dig Liver Dis; 2007 Jun; 39(6):589-96. PubMed ID: 17459794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
    Maillard M; Burnier M
    Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals.
    Fosbøl EL; Køber L; Torp-Pedersen C; Gislason GH
    Expert Opin Drug Saf; 2010 Nov; 9(6):893-903. PubMed ID: 20569079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke.
    Haag MD; Bos MJ; Hofman A; Koudstaal PJ; Breteler MM; Stricker BH
    Arch Intern Med; 2008 Jun; 168(11):1219-24. PubMed ID: 18541831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of nonsteroidal antiinflammatory drugs: is there a change in patient risk profile after withdrawal of rofecoxib?
    Rahme E; Roussy JP; Lafrance JP; Nedjar H; Morin S
    J Rheumatol; 2011 Feb; 38(2):195-202. PubMed ID: 21078717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury.
    Winkelmayer WC; Waikar SS; Mogun H; Solomon DH
    Am J Med; 2008 Dec; 121(12):1092-8. PubMed ID: 19028206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin.
    ; Wilcox CM; Allison J; Benzuly K; Borum M; Cryer B; Grosser T; Hunt R; Ladabaum U; Lanas A; Paulus H; Regueiro C; Sandler RS; Simon L
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1082-9. PubMed ID: 16877048
    [No Abstract]   [Full Text] [Related]  

  • 34. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
    Mitchell JA; Warner TD
    Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The murky waters of the coxibs: a review of the current state of play.
    Ostor AJ; Hazleman BL
    Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [What is new about nonsteroidal antiinflamatory drugs?].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2007 Dec; 23(138):454-8. PubMed ID: 18432131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.
    Patterson MK; Castellsague J; Walker AM
    Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):982-8. PubMed ID: 18711705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ; Cleland LG
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selectivity of NSAIDs for COX-2 and cardiovascular outcome.
    Maxwell SR; Payne RA; Murray GD; Webb DJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):243-5. PubMed ID: 16842401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.